Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumab Eptinezumab is an investigational... LEARN MORE
The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.